VVUS 5 Day 30 Min

Vivus(VVUS) is now up 8% at above $13, reversing earlier losses that saw it touch a day low $11.42 after opening at $11.53. It had dropped 3% pre-market. The gains come despite it reporting a wider Q1 loss versus year ago and missing revenue estimates.

The company, in its earnings conference call earlier today, said that it is in talks with larger pharmaceutical companies as part of its efforts to expand commercialization of its weight management drug, Qsymia, according to a report on StreetInsider. VVUS intends to make Qsymia available though retail pharmacies by the middle of July, the report added.

The company earlier reported net loss of $53.6 million or $0.53 per share, as compared to a net loss $18.8 million or $0.20 per share in the comparable quarter a year ago. Analysts, on average, forecast a loss of $0.50 per share on $5.2 million in revenue. It had $4.1 million in Qsymia sales this quarter compared to none a year earlier.

VVUS Short Float 28.74%

 

 

 

10 Day 30 Minutes

 

 

Year To Date